active
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Added more to my great nieces/nephews college fund today @4.68.... yeah my baby niece had triplets on us, so it’s going to be costly!
Bhahahaha
Just added 1.5k to my portfolio.....
Great stuff even if the share price doesn’t reflect it!!! THANKS
Missed earnings I wonder how we gonna hold up?
Thanks for the info brother!
I hope you are right!
GILD news took a little steam from us.
Oops.....
[/RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary b]
GlobeNewswire GlobeNewswire•April 28, 2020
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies
---
H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population
---
https://finance.yahoo.com/news/redhill-biopharma-strengthens-coverage-talicia-110010706.html
Stimulus chech got it today... drum roll-BOUGHT MORE NBRV!!!
I must confess to the board, I put in an order earlier today for more RDHL but cancelled and bought more NBRV with my Stimulus check. Next time more RDHL!
I was bracing for a pull back, glad I was wrong!
Good stuff, keep it coming brother!
I think I want my 500 shares back!??
Will AQST Report Negative Earning Next Week?
Zack’s Equity
Aquestive Therapeutics (AQST) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2020. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 5. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This specialty pharmaceutical company is expected to post quarterly loss of $0.52 per share in its upcoming report, which represents a year-over-year change of +11.9%.
Revenues are expected to be $10.90 milli.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
For Aquestive Therapeutics, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination makes it difficult to conclusively predict that Aquestive Therapeutics will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
influence on the upcoming number.
For the last reported quarter, it was expected that Aquestive Therapeutics would post a loss of $0.45 per share when it actually produced a loss of $0.48, delivering a surprise of -6.67%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Aquestive Therapeutics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release
RedHill announces expanded coverage of Talicia in U.S.
Apr. 28, 2020 10:44 AM ET|About: RedHill Biopharma Ltd. (RDHL)|By: Douglas W. House, SA News Editor
RedHill Biopharma (RDHL -11.5%) announces that pharmacy benefit manager Prime Therapeutics has added Talicia (omeprazole magnesium, amoxicillin and rifabutin) to its A-Series National Formulary as an unrestricted preferred brand for H. pylori treatment effective July 1.
Prime serves 23 Blue Cross Blue Shield plans covering 30M members.
The negative action appears to be profit-taking after its 90% run-up in this month.
https://seekingalpha.com/news/3565328-redhill-announces-expanded-coverage-of-talicia-in-u-s
Thanks for highlighting those 2 important points my friend!!!
Funny, my accountant friend sent me the same caution.... love you brother-thanks
I definitely gotta remember that witH NBRV I’m heavily overloaded with that stock!
Amen brother the biggest gainer in my portfolio today was AQST!
The 2nd was you know RDHL!
In fact all my stocks are up today!!!
That’s GREAT NEWS my friend.... too bad retreat and others left.
WOW, keep it coming!!!
Great news! Thanks!
Projections for the week anyone?
Aquestive Therapeutics Inc. (AQST)
Next up is biotech Aquestive Therapeutics, which uses innovative drug delivery technology to redesign important medicines. With not one but two upcoming PDUFA dates, it’s not surprising that members of the Street think its $3.55 share price represents the ideal entry point.
Weighing in for H.C. Wainwright, five-star analyst Raghuram Selvaraju believes that the most valuable piece of the puzzle is its anti-seizure candidate, Libervant, the PDUFA date for which is slated for September 27. “We estimate that Libervant could generate U.S. sales approaching $300 million by 2030. Libervant has been accorded Orphan Drug status, which would confer seven-year market exclusivity upon the product if approved,” he explained.
Regarding Libervant’s launch, Selvaraju argues the fact that Sympazan (clobazam), an oral film for Lennox-Gastaut syndrome (LGS)-associated seizures, was launched prior to Libervant provides Aquestive with the opportunity to set up its commercial infrastructure.
It should also be noted that Selvaraju sees the recent share price weakness as not fully reflecting AQST’s value, with it boasting several other promising candidates in its pipeline. “In our view, the recent coronavirus crisis-driven market disruption has resulted in massively overdone attrition in Aquestive's share price. The company currently trades at a sub-$60 million market cap, which we believe does not reflect even the value of its manufacturing and licensing-related revenue, let alone revenue generated from its proprietary products,” he commented.
One of these candidates is APL-130277, which could be approved on May 21. On top of this, AQST-108 could enter clinical testing this year, and with the annual U.S. epinephrine product market potentially totaling $5.2 billion by 2026, according to Coherent Market Insights, Selvaraju highlights the large opportunity for the biotech.
As a result, Selvaraju reiterated a Buy rating and $13 price target. Should this target be met, a twelve-month gain of 266% could be in the cards. (To watch Selvaraju’s track record, click here)
Feeling good investors, please let me share a Bible message that makes me feel this way....
King James Bible Online...
1 Corinthians
2:9
“But as it is written, Eye hath not seen, nor ear heard, neither have entered into the heart of man, the things which God hath prepared for them that love him.”
I believe he was quoting from.....
Isaiah
52:15
“So shall he sprinkle many nations; the kings shall shut their mouths at him: for that which had not been told them shall they see; and that which they had not heard shall they consider.”
64:4
“For since the beginning of the world men have not heard, nor perceived by the ear, neither hath the eye seen, O God, beside thee, what he hath prepared for him that waiteth for him.”
It has got interesting!!!!
I can see the possibilities!!!!!
Thanks, they are killing me!
KingBach I owe you a BIG APOLOGY and I can honestly say, “GLAD YOU WERE”
So far anyway!
Certainly got more potential than I was expecting Whoooooaaaaa!!!!
RDHL strikes AGAIN....
Raleigh pharma to have second drug tested for potential COVID-19 treatment
https://www.bizjournals.com/triangle/news/2020/04/21/raleigh-pharma-to-have-second-drug-tested-for.html?ana=yahoo&yptr=yahoo
Man I hate these POP UP ADDS just getting into reading your post and here comesb E*TRADE pop/up which took a few minutes to get back to your post. Anybody else experiencing this problem?
GREAT NEWS bodes well for the future!
Good news on a bad day??
Now we need the HYPE INVESTOR!!!!!
Ditto Investor!!!
Thanks, adding it to my watch list!
ADHD NDA Filing NDA submission announced March 2, 2020.
Exservan (riluzole) Oral Film Amyotrophic Lateral Sclerosis Approved FDA Approval announced November 22, 2019.
Sympazan Lennox-Gastaut Syndrome Approved Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Libervant - AQST-203 Epileptic seizures PDUFA PDUFA date September 27, 2020.
AQST-119 Erectile dysfunction CRL CRL issued November 16, 2018.
APL-130277 Parkinson’s Disease with motor fluctuations PDUFA CRL issued January 30, 2019 through partner Sunovion (private company). NDA refiled. New PDUFA date May 21, 2020.
AQST-108 Anaphylaxis Phase 1 Pivotal pharmacokinetic (PK) trials to be initiated before the end of 2020
Simplified version, click on link...
https://www.biopharmcatalyst.com/company/AQST
Be sure to CLICK ON DRUG INFORMATION
Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions
Zacks Equity Research
ZacksApril 15, 2020, 8:50 AM EDT
One stock that might be an intriguing choice for investors right now is Aquestive Therapeutics, Inc. AQST. This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
https://finance.yahoo.com/news/aquestive-therapeutics-aqst-strong-industry-125012129.html
Good one King!
What there’s about a 100 CO’s around the world working on Covin-19 cure?
Anyone think any Co gonna have a cure alone?
Hype train Covin-19 all ahead!
Thanks for starting this board my friend!